Literature DB >> 8918571

Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice.

M M Newkirk1, J Novick, M M Stevenson, M J Fournier, P Apostolakos.   

Abstract

In order to understand better the origins of the elevated levels of the glycoform of IgG that lacks galactose on both arms of the oligosaccharide chain (G0%) located in the Fc, which occurs in man and mouse with age, and in particular in autoimmune disease, we investigated the clearance of two glycosylated forms of IgG2a and IgG1 in normal (BALB/c) and autoimmune-prone (MRL/1pr, MRL/+, and non-obese diabetic (NOD)) mice. To investigate the possibility of different rates of catabolism, enzymatically generated glycoforms of monomeric IgG1 and IgG2a (fully glycosylated or G0%), were iodinated and injected into the tail vein of the mice. We found that the G0% IgG2a remained in circulation significantly longer than the fully glycosylated variants, in all of the mouse strains tested. In contrast, the two forms of IgG1 had similar kinetics in all the autoimmune-prone mice, whereas in BALB/c, there was a longer half-life (t1/2) for G0% IgG1. These data suggest that there may be differences in the ability of the IgG glycoforms to bind to the Fc gamma receptors, in particular Fc gamma RI. The clearance rates were found to vary among the strains studied, with MRL/1pr having the fastest catabolic rates for all glycoforms and IgG subclasses tested. This appeared to be due to the presence of circulating IgG and IgM rheumatoid factors (RF). There were significantly increased frequencies and titres for both IgM and IgG RF in MRL/1pr mice compared with the other strains. In contrast, interferon-gamma, known to induce the Fc gamma RI, was found to be similar in the sera, in all of the strains of mice examined. These results suggest that RF probably play an important biological function in the MRL/1pr mice and aid in the clearance of circulating IgG. Our study shows that the state of glycosylation of IgG affects the t1/2 in vivo, and that by removing the terminal sugars (sialic acid and galactose), the antibody (IgG2a) will remain in circulation significantly longer. These observations may thus provide a partial explanation for the increase in relative percentage of this glycoform that occurs with age.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8918571      PMCID: PMC2200602          DOI: 10.1046/j.1365-2249.1996.d01-847.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Hannah Joerissen; Beate Müller-Tiemann; Heiner Apeler; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-03       Impact factor: 2.695

Review 2.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 3.  Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.

Authors:  Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-15       Impact factor: 2.745

Review 4.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

Review 5.  Assessing monoclonal antibody product quality attribute criticality through clinical studies.

Authors:  Andrew M Goetze; Matthew R Schenauer; Gregory C Flynn
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

Review 6.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 7.  Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.

Authors:  Yulia Vugmeyster; John Harrold; Xin Xu
Journal:  AAPS J       Date:  2012-07-14       Impact factor: 4.009

8.  Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys.

Authors:  Maya K Leabman; Y Gloria Meng; Robert F Kelley; Laura E DeForge; Kyra J Cowan; Suhasini Iyer
Journal:  MAbs       Date:  2013 Nov-Dec       Impact factor: 5.857

9.  Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.

Authors:  Zhe Li; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-26       Impact factor: 2.745

10.  A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy.

Authors:  Rick Kapur; Iwan Kustiawan; Anne Vestrheim; Carolien A M Koeleman; Remco Visser; Helga K Einarsdottir; Leendert Porcelijn; Dave Jackson; Belinda Kumpel; André M Deelder; Dennis Blank; Björn Skogen; Mette Kjaer Killie; Terje E Michaelsen; Masja de Haas; Theo Rispens; C Ellen van der Schoot; Manfred Wuhrer; Gestur Vidarsson
Journal:  Blood       Date:  2013-11-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.